Altiratinib - CAS# 1345847-93-9 Catalog No.:M7125-10 while 5 of 5 mice

while 5 of 5 mice treated with vehicle shows tumor growth

1007/s00280-011-1662-4

1418033-25-6

InChi: InChI=1S/C19H19N5O/c1-13-6-4-5-7-17(13)23-22-15-8-9-16(14(2)12-15)21-19(25)18-10-11-20-24(18)3/h4-12H

It blocks Wnt-dependent phosphorylation of Lrp6 receptor and Dvl2

Altiratinib - CAS# 1345847-93-9 Catalog No.:M7125-10 while 5 of 5 miceAltiratinib, CAS No. 1345847 93 9, also known as DCC 270, DP 5164, is an oral, selective and highly potent inhibitor of MET, TIE2, VEGFR2 and TRK kinases with potential anticancer activity. DCC 2701 effectively reduces tumor burden in vivo and blocks c MET pTyr(1349) mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro. Importantly, DCC 2701's anti proliferative activity was dependent on c MET activation induced by